个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Yana Ma[1,2] ; Jiale Liu[1,2] ; Ning Li[3] ; Hualei Bu[1] ; Yongwen Huang[4] ; Chengjuan Jin[5] ; Hao Wen[6] ; Shuai Feng[7] ; Hui Zhang[8] ; Xiaorong Yang[9] ; Beihua Kong[1,2] ; Lingying Wu[3] ; Kun Song[1,2] ;
机构： [1]Department of Obstetrics and Gynecology, Qilu Hospital of ShandongUniversity, 107 Wenhua Xi Road, Jinan 250012, Shandong Province,China [2]Gynecologic Oncology Key Laboratory of Shandong Province,Qilu Hospital of Shandong University, Jinan 250012, China [3]Departmentof Gynecologic Oncology, National Cancer Center/National Clinical ResearchCenter for Cancer/Cancer Hospital, Chinese Academy of Medical Sciencesand Peking Union Medical College, No.17Panjiayuan Nanli, Beijing 100021,Chaoyang District, China [4]Gynecologic Department, Sun Yat-sen UniversityCancer Center, Guangzhou 510060, China [5]Department of Obstetricsand Gynecology, School of Medicine, Shanghai General Hospital, ShanghaiJiao Tong University, Shanghai 201620, China [6]Department of GynecologicOncology, Fudan University Shanghai Cancer Center, Shanghai 201620,China [7]Gynecological Oncology Department, Shandong Cancer Hospitaland Institute, Shandong First Medical University and Shandong Academyof Medical Sciences, Jinan 250012, China [8]Department of Gynecology,The Fourth Hospital of Hebei Medical University, Shijiazhuang 050000,China [9]Clinical Epidemiology Unit, Qilu Hospital of Shandong University,Jinan 250012, China
出处：
DOI： 10.1186/s13048-023-01283-2
ISSN：

关键词： PARPi monotherapy Platinum-sensitive recurrence BRCA1/2 mutation Post-recurrence survival

摘要：
The therapeutic effect of poly (ADP-ribose) polymerase inhibitors (PARPi) monotherapy compared with platinum-based chemotherapy, and the impact to subsequent platinum-based chemotherapy after PARPi resistance were inconclusive in breast cancer susceptibility genes (BRCA)1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse.BRCA1/2-mutated patients with secondary platinum-sensitive relapse included in this study did not receive any maintenance regimen after first- and second-line platinum-based chemotherapy, and the secondary platinum-free interval (PFI) was more than 6 months. Patients in study group were treated with PARPi monotherapy until disease progression, and patients in control group were treated with platinum-based chemotherapy without restriction. Progression-free survival (PFS) was defined as the time from third-line therapy to disease progression or death, PFS2 was defined as the time from platinum-based chemotherapy after PARPi resistance to next subsequent therapy or death. Post-recurrence survival (PRS) refers to the survival time after secondary platinum-sensitive relapse.A total of 119 patients were retrospectively analyzed, including 71 (59.7%) in study group and 48 (40.3%) in control group. The objective response rate (ORR: 77.5% vs. 80.0%, p=0.766) and PFS (median: 11.2 vs. 11.0 months, p=0.962) were comparable. The benefit of subsequent platinum-based chemotherapy after PARPi resistance was more pronounced in patients with PARPi treatment for more than 12 months (median PFS2: 8.6 vs. 4.3 months, p=0.040). PARPi monotherapy had no adverse effect on PRS compared with platinum-based chemotherapy (median PRS:41.2 vs. 42.8 months, p=0.323). Compared to patients in control group who had never received PARPi, PARPi monotherapy (median PRS: 41.2 vs. 33.7 months, p=0.019) and post-line treatment with PARPi in the control group (median PRS: 48.1 vs. 33.7 months, p=0.002) could prolong PRS for patients with secondary platinum-sensitive relapse.PARPi monotherapy was similar to platinum-based chemotherapy for BRCA1/2-mutated ovarian cancer patients with secondary platinum-sensitive recurrence, and could improve prognosis.© 2023. The Author(s).

基金：
This study was supported by the National Key Technology Research andDevelopment Programme of China (2022YFC2704200 and 2022YFC2704202),and Natural Science Foundation of Shandong Province (grant ZR2021QH050).
语种：
外文
WOS：
PubmedID：
中科院分区：
出版当年[2023]版：
大类 | 3 区 医学
小类 | 3 区 生殖生物学
最新[2025]版：
大类 | 2 区 医学
小类 | 2 区 生殖生物学
JCR分区：
出版当年[2023]版：
Q1 REPRODUCTIVE BIOLOGY
最新[2024]版：
Q1 REPRODUCTIVE BIOLOGY

影响因子： 最新[2024版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版] 出版后一年[2024版]

第一作者：
第一作者机构： [1]Department of Obstetrics and Gynecology, Qilu Hospital of ShandongUniversity, 107 Wenhua Xi Road, Jinan 250012, Shandong Province,China [2]Gynecologic Oncology Key Laboratory of Shandong Province,Qilu Hospital of Shandong University, Jinan 250012, China
通讯作者：
通讯机构： [1]Department of Obstetrics and Gynecology, Qilu Hospital of ShandongUniversity, 107 Wenhua Xi Road, Jinan 250012, Shandong Province,China [2]Gynecologic Oncology Key Laboratory of Shandong Province,Qilu Hospital of Shandong University, Jinan 250012, China
推荐引用方式(GB/T 7714)：
Yana Ma,Jiale Liu,Ning Li,et al.Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse[J].JOURNAL OF OVARIAN RESEARCH.2023,16(1):doi:10.1186/s13048-023-01283-2.
APA：
Yana Ma,Jiale Liu,Ning Li,Hualei Bu,Yongwen Huang...&Kun Song.(2023).Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse.JOURNAL OF OVARIAN RESEARCH,16,(1)
MLA：
Yana Ma,et al."Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse".JOURNAL OF OVARIAN RESEARCH 16..1(2023)

相关文献

[1]An open-label, multi-center, single-arm, phase 2 study of fluzoparib in patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian cancer. [2]Efficacy of PARPi monotherapy and the impact of subsequent platinum-based chemotherapy in BRCA1/2 mutant ovarian cancer patients with secondary platinum-sensitive relapse [3]VEP-M在视觉通路病变中的应用价值(附18例报道) [4]智能化舌体(形)测算仪的研制及应用-附1733例患者检测初步分析 [5]阿帕替尼治疗腹腔低度恶性肌纤维母细胞肉瘤1例及文献回顾 [6]肺结节中西医结合全程管理专家共识 [7]早发型胃癌的特点及研究进展 [8]micrornas在口腔扁平苔藓组织中的表达谱分析及3种mirna的血清学表达 [9]基于cesm影像与病理指标预测乳腺癌her-2和ki-67表达的价值 [10]grhl2与雌激素相关性肿瘤发展关系的研究进展

资源点击量：42329 今日访问量：0 总访问量：1365 更新日期：2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持：重庆聚合科技有限公司 地址：河北省石家庄市健康路12号